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Purpose of the study
Despite risk of hypersensitivity (HS), nevirapine (NVP)
underpins first-line HIV therapy in Africa. The relation-
ship between NVP exposure and HS is unknown but
could be influenced by polymorphisms in CYP2B6 and
CYP3A4 affecting drug metabolism.
Methods
180 HIV patients (101 female) from Malawi receiving
NVP-based therapy (200mg twice daily) between March
2007-September 2008 for a median (range) 6weeks (1-
26) were included in the population pharmacokinetic
(PK) model (n=383 NVP serum concentrations). Rich
and sparse (n=40 and 140 patients, respectively) sam-
pling was performed. Median (range) age, weight, BMI
and CD4 cell count were 34yr (21-62), 54kg (35-94),
20kg/m
2 (15-38) and 156cells/mm
3 (1-812). In total 25
individuals were HS and 23 hepatitis B/C co-infected.
Pharmacogenetic data were available for single nucleo-
side polymorphisms (SNPs) CYP3A5*6, CYP3A5*3,
CYP2B6 983T>C, CYP2B6 516G>T, CYP2B6 785A>G in
89/180 patients obtained by Sequenom iPLEX. NON-
MEM (VI 2.0) was applied to determine NVP PK para-
meters, interindividual, interoccasion variability (IIV,
IOV), residual error and influence of patient demo-
graphics, HS and genetics on NVP apparent oral clear-
ance (CL/F). A visual predictive check was used to vali-
date the model.
Summary of results
A one compartment model with first order absorption
best described NVP concentrations. For the final model
(n=89) NVP CL/F (relative standard error; RSE%) was
2.67 (5%) with IIV and IOV of 30% (29%) and 32%
(26%), respectively. Apparent volume of distribution and
absorption rate constant were 141L (22%) and 0.77h
-1
(31%), respectively. None of the patient demographics
were significantly related to NVP CL/F. No association
between NVP CL/F and HS or hepatitis infection was
observed. Of the SNPs analysed CYP2B6 983T>C and
CYP3A5*3 had a significant impact on NVP CL/F; redu-
cing it by 25% in 983C heterozygotes (allelic frequency
18%) and 40% in CYP3A5*3 homozygotes (allelic fre-
quency 5%).
Conclusions
Available patient demographics and development of HS
were not associated with NVP CL/F in this population
of HIV-infected patients from Malawi. Genes associated
with loss of function in CYP2B6 and CYP3A5 reduced
NVP CL/F. However, NVP exposure was not associated
with the development of HS, which is more likely to be
an immunological phenomenon.
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